Michael Goldberg

Michael Goldberg is the founder and CEO of SURGE Therapeutics, a Cambridge, Massachusetts biotech pioneering intraoperative immunotherapy. His idea is deceptively simple: when a surgeon removes a solid tumor, don't leave the cavity empty - fill it with an injectable, biodegradable hydrogel that releases immune-activating medicine right where cancer is most likely to return. A trained chemist who earned a PhD at MIT under Robert Langer and did postdoctoral work with Nobel laureate Phillip Sharp, Goldberg became a Harvard Medical School professor before leaving academia to translate his lab's discovery into the clinic. SURGE has raised roughly $58M, cleared an FDA IND, and completed Phase 1 dosing of its lead program ahead of a registrational trial in triple-negative breast cancer.